IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs. The company was founded in 2015 and is based in Daejeon, South Korea.
Metrics to compare | 287840 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship287840PeersSector | |
---|---|---|---|---|
P/E Ratio | −42.5x | −10.2x | −0.6x | |
PEG Ratio | −0.88 | −0.07 | 0.00 | |
Price/Book | 97.2x | 2.6x | 2.6x | |
Price / LTM Sales | 129.0x | 28.1x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 39.1% | |
Fair Value Upside | Unlock | 10.0% | 4.5% | Unlock |